Publications and Submissions

The 11th International VHL Medical Symposium

Madrid, Spain Oct 23-24, 2014

Presentation summaries from the VHL Alliance website

Turcotte Cancer Research Group

Tumor Microenvironment and Cellular Stress: Signaling, Metabolism, Imaging and Therapeutic Targets

Chania, Greece October 4 - 9, 2012

Dre. Sandra Turcotte PhD

Group leader and Principal Investigator

International Scientific Meetings

Keystone Symposia on Hypoxia: From Basic Mechanisms to Therapeutics

Dublin, Ireland May 12-17, 2015

Conference

Bouhamdani N, Cormier K, Coholan A, Giaccia AJ, Mes-Masson AM, Bertrand R and Turcotte S. Autophagy and lysosomal rupture sensitizes VHL-inactivated Renal Cell Carcinoma. Submitted to EMBO J

Cuperlovic-Culf M, Cormier K, Touaibia M, Reyjal J, Robichaud S, Belbraouet M and Turcotte S. 1H NMR Metabolomics analysis of renal cell carcinoma cells: VHL and HIF effects on metabolism. International J. Cancer 15 may 2016.

21) Cormier K, Curry RD, Betsch MP, Goguen JA, Vogels CH, Decken A, Turcotte S and Westcott SA. Synthesis, characterization, and anticancer activities of pyrogallol-based arylspiroborates. Journal of Heterocyclic Chemistry, article first published online 27 July 2015, DOI:10.1002/jhet.2490.

20) Jean S, Cormier K, Patterson AE, Vogels CM, Decken A, Robichaud G, Turcotte S and Westcott SA. Synthesis, characterization and anticancer properties of organometallic Schiff base platinum complexes. Canadian Journal of Chemistry, Publish on the web 21 May 2015, 10.1139/cjc-2015-0157.

19) Reyjal J, Cormier and Turcotte S. Autophagy and programmed cell death to target cancer cells : exploiting synthetic lethality as cancer therapeutic. Adv. Exp. Biol. 772, 167-188, 2014

18) Reaume N, Graham GE, Tomiak E, Kamel-Reid S, Jewett MAS, Bjarnason G, Blais N, Care M, Drachenberg D, Gedye C, Grant R, Heng D, Kollmannsberger C, Lattouf JB, Pause A, Reuther D, Soulieres D, Tanguay S, Turcotte S, Violette P, Wood L, Basiuk J and Pautler SE, Canadian Guideline on Genetic Screening for Hereditary Renal Cell Carcinoma. Can Urol Assoc J. 9-10, 319-323, 2013.

17) Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EL, Wu J, Solow-Cordero DE, Bouley DM, Graves EE, Denny WA, Hay MP, Giaccia AJ. Targeting GLUT1 and the Warburg Effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 3(3), 94-107, 2011.

16) Turcotte S and Giaccia AJ. Targeting cancer cells through autophagy for anticancer therapy. Curr Opin in Cell Biol. 22 (2), 246-251,2010.

15) Hay MP, Turcotte S, Flanagan JU, Bonnet M, Chan DA, Sutphin PD, Nguyen P, Giaccia AJ and Denny WA. 4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death. J. Med. Chem. 53(2), 787-797, 2010.

14) Turcotte S, Sutphin PD and Giaccia AJ. Targeted therapy for the loss of von Hippel-Lindau in Renal Cell Carcinoma: A novel molecule that induces autophagic cell death. Autophagy 4(7), 2008.

13) Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA and Giaccia AJ. A molecule targeting VHL-deficient Renal Cell Carcinoma that induces autophagy. Cancer Cell 14(1):90-102, 2008.

12) Turcotte S, and Giaccia AJ. Targeted Therapy for the Loss of the Tumor Suppressor Gene von Hippel-Lindau through Synthetic Lethality, Am Soc Clin Oncol Ed Book 2008: p. e15-e18.

11) Barakat S, Turcotte S, Demeule M, Lachambre MP, Régina A, Baggetto LG, Béliveau R. Regulation of brain endothelial cells migration and angiogenesis by P-glycoprotein/caveolin-1 interaction. Biochim. Biophys. Res. Commun, 372(3), 440-446, 2008.

10) Sutphin PD, Chan DA, Li J, Turcotte S, Krieg A, and Giaccia AJ. Targeting the loss of the VHL tumor suppressor gene in renal cell carcinoma cells, Cancer Research 67(12):5896-905, 2007.

9) Chan DA, Krieg AJ, Turcotte S, and Giaccia AJ. HIF Gene Expression in Cancer Therapy. Oxygen Biology and Hypoxia, Methods in Enzymology, volume 435, Chapter 16, Helmut Sies (Serial Volume Editor), Bernard Bruene (serial Volume Editor), ISBN: 978-0-12-373970-4 2007.

8) Turcotte S, Demeule M, Régina A, Jodoin J, Fournier C, Moghrabi A, and Béliveau R. The blood-brain barrier: Roles of the multidrug resistance transporter P-glycoprotein. Chapter 19 Blood-Brain Barriers: From Ontogeny to Artificial Interfaces, Rolf Dermietzel (Editor), David C. Spray (Editor), Maiken Nedergaard (Editor), ISBN: 3-527-31088-6.

7) Desrosiers RR, Cusson M-H, Turcotte S, Béliveau R. The farnesyltransferase inhibitor SCH-66336 down-regulates secretion of matrix proteinases and inhibits carcinoma cell migration International Journal of Cancer 114, 702-712, 2005.

6) Demeule M, Brossard M, Turcotte S, Régina A, Jodoin J, and Béliveau R. Diallyl disulfide, a chemopreventive agent in garlic, induces multidrug resistance-associated protein 2 expression Biochim. Biophys. Res. Commun. 324, 937-945, 2004.

5) Turcotte S, Desrosiers RR, Brand G, and Béliveau R. von Hippel-Lindau tumor supressor protein stimulation by thrombin involves RhoA activation in renal cell carcinoma International Journal of Cancer 112, 777-786, 2004.

4) Turcotte S, Desrosiers RR, and Béliveau R. Hypoxia up-regulates von Hippel-Lindau tumor suppressor protein through RhoA-dependent activity American Journal of Physiology, Renal Physiology 286: F338-F348, 2004.

3) Turcotte S, Desrosiers RR, and Béliveau R. HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal carcinoma cells. Journal of Cell Science 116: 2247-2260, 2003.

2) Annabi B, Lee YT, Turcotte S, Naud E, Desrosiers RR, Champagne M, Eliopoulos N, Galipeau J, Beliveau R. Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells. 21:337-347, 2003.

1) Turcotte S, and Averill D. A. Sensitization to the cytotoxicity of melphalan by ethacrynic acid and hyperthermia in drug-sensitive and multidrug-resistant chinese hamster ovary cells. Radiation Research 156: 272-282, 2001.